Rani Therapeutics Holdings, Inc. (RANI)
Nasdaq · Healthcare · Biotechnology
$0.7749−4.43%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $109M
- 52-week range
- $0.445 – $3.87
- 52-week change
- +62.20%
- EPS (trailing)
- −$0.15
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $1.6M (+58.85%)
- Net income
- −$29.7M
- Operating margin
- −2346.0%
- Diluted EPS
- −$0.45
- Free cash flow
- −$18.8M
From the company’s annual report on SEC EDGAR.
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd.
Headquarters: San Jose, United States · 69 employees · ranitherapeutics.com